Juno Therapeutics (JUNO) Misses Q3 EPS by 12c, Offers Guidance

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/12/2026

1. MIRM
2. SPY
3. MSFT
4. META
5. PLTR
6. CSCO
7. KTOS
8. LDOS
9. BMY
10. LBRX

Go back to Juno Therapeutics (JUNO) Misses Q3 EPS by 12c, Offers Guidance

Juno Therapeutics Reports Third Quarter 2015 Financial Results

November 10, 2015 4:05 PM EST

Company-wide progress in advancing product candidates and building capabilities

Conference call to be held today at 5:00 p.m. Eastern Time

SEATTLE--(BUSINESS WIRE)-- Juno Therapeutics, Inc. (NASDAQ: JUNO), a biopharmaceutical company focused on re-engaging the bodys immune system to revolutionize the treatment of cancer, today reported business highlights and financial results for the third quarter of 2015.

We continue to make progress in the clinic and building our capabilities. We began a trial that we expect will support registration of JCAR015 in... More